ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
NCT01600079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1505647
Last updated 2022-07-14
Summary
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
Conditions
- Herpes Zoster
- Shingles
Interventions
- BIOLOGICAL
-
ZOSTAVAX™
ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
Sponsors & Collaborators
-
Kaiser Permanente
collaborator OTHER - lead INDUSTRY
Principal Investigators
-
Medical Director · Merck Sharp & Dohme LLC
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-05-15
- Primary Completion
- 2020-10-16
- Completion
- 2020-10-16
More Related Trials
-
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
NCT02519855 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
NCT01165177 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
NCT01527370 ·Status: COMPLETED ·Phase: PHASE3
-
Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)
NCT00681031 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects
NCT01295320 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
NCT00561080 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
NCT01245751 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
NCT01391546 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
NCT01385566 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
NCT01165229 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
NCT00231816 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
NCT02114333 ·Status: COMPLETED ·Phase: PHASE1
-
ZOSTAVAX(R) Local Registration Trial (V211-019)
NCT00444860 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
NCT00886613 ·Status: COMPLETED ·Phase: PHASE1
-
ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
NCT00535730 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
NCT00109122 ·Status: COMPLETED ·Phase: PHASE2
-
A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)
NCT02180295 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)
NCT01505647 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
NCT07293065 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
NCT03314103 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
NCT02979639 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
NCT00130793 ·Status: COMPLETED ·Phase: PHASE3
-
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
NCT05219253 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
NCT05856084 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
NCT01610414 ·Status: COMPLETED ·Phase: PHASE3